Effects of Nateglinide on Postprandial Glucose Excursion by Restoring Early Phase Insulin Secretion

Exclusion Criteria

• •1. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (\>5 mIU/mL).
• •2. With known hypersensitivity to Nateglinide, Acarbose or any of the excipients.
• •3. A history of,
• •1. type 1 diabetes, diabetes that is a result of pancreatic injury, or secondary forms of diabetes, e.g., Cushing's syndrome and acromegaly.
• •2. acute metabolic diabetic complications such as ketoacidosis or hyperosmolar state (coma) within the past 6 months.
• •3. Torsades de pointes, sustained and clinically relevant ventricular tachycardia or ventricular fibrillation.
• •4. percutaneous coronary intervention within the past 3 months.
• •5. any of the following within the past 6 months: myocardial infarction (MI), coronary artery bypass surgery, unstable angina, or stroke.
• •4. Evidence of significant diabetic complications, e.g., symptomatic autonomic neuropathy or gastroparesis.
• •5. Acute infections which may affect blood glucose control within 4 weeks prior to visit 1.
• •6. Congestive heart failure requiring pharmacologic treatment. mg/dL (123μmol/L)